AMPD3 Antibody

What is AMPD3 and what is its primary cellular function?

AMPD3 (Adenosine Monophosphate Deaminase 3) is a highly regulated enzyme of approximately 90 kDa that catalyzes the hydrolytic deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP), representing a branch point in the adenylate catabolic pathway. It belongs to a family of AMP deaminases, with AMPD3 specifically encoding the erythrocyte (E) isoform, while other family members encode isoforms predominant in muscle (AMPD1) and liver (AMPD2) cells. AMPD3 plays a crucial role in regulating intracellular adenine nucleotide concentrations and subsequently affects cellular energy metabolism .

What types of AMPD3 antibodies are available for research?

There are multiple types of AMPD3 antibodies available for research applications:

Different formulations exist including unconjugated, purified, BSA-free, and prediluted versions optimized for specific applications .

What is the optimal dilution range for AMPD3 antibodies in various applications?

The optimal dilution varies by application and specific antibody:

It is strongly recommended to titrate antibodies in each specific testing system for optimal results, as the effective concentration may vary depending on tissue type, fixation method, and detection system .

What antigen retrieval methods are optimal for AMPD3 immunohistochemistry?

For formalin-fixed, paraffin-embedded (FFPE) tissues, two main antigen retrieval methods have been validated:

• Heat-induced epitope retrieval in 10 mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at room temperature for 20 minutes.

• Alternative method using 10 mM Tris with 1 mM EDTA, pH 9.0, heating tissue sections for 45 minutes at 95°C followed by cooling at room temperature for 20 minutes.

The choice between these methods may depend on the specific tissue type and antibody used. For certain tissue types like tonsil and placenta, the pH 9.0 method has shown excellent results as evidenced by immunohistochemistry images .

How should AMPD3 antibodies be stored to maintain optimal reactivity?

Storage conditions vary slightly by antibody formulation:

• Standard antibody preparations: Store at 2 to 8°C

• Fluorescent conjugates: Store at 2 to 8°C and protect from light

• BSA-free antibodies: Store at -10 to -35°C

• Some antibody formulations: Store at -20°C with 0.02% sodium azide and 50% glycerol at pH 7.3

Most commercial AMPD3 antibodies are stable for at least 24 months from the date of receipt when stored as recommended. Repeated freeze-thaw cycles should be avoided for all antibody preparations. For long-term storage of concentrated antibodies, aliquoting is recommended .

What is the role of AMPD3 in cancer, and how can antibodies help elucidate this relationship?

AMPD3 has demonstrated significant down-regulation in cancerous tissues of head and neck squamous cell carcinoma (HNSCC), with this down-regulation correlating with more advanced tumor and clinical stages. Patients with higher AMPD3 expression showed better 5-year survival rates. Interestingly, AMPD3 knockdown in SCC-4 and SCC-25 cell lines demonstrated reduced cellular proliferation but increased migration and invasion capabilities .

AMPD3 antibodies can be utilized to:

• Quantify AMPD3 expression levels via western blotting and correlate with disease progression

• Perform immunohistochemical analysis of patient biopsies to stratify patients based on AMPD3 expression

• Investigate cellular localization changes in cancer cells using immunofluorescence

• Study the diagnostic utility of AMPD3 in erythroid cancers, particularly erythroleukemia

How is AMPD3 involved in skeletal muscle atrophy, and what experimental approaches using antibodies can investigate this?

AMPD3 is one of the most highly upregulated genes in atrophic muscle. Overexpression of AMPD3 in mouse tibialis anterior muscles and C2C12 myotubes significantly decreased ATP concentrations (by 25% and 16%, respectively) and increased IMP levels with subsequent production of IMP catabolites (inosine, hypoxanthine, and uric acid) .

Prolonged AMPD3 expression (48 hours) reduced:

• pAMPK/AMPK ratio by 24%

• Phosphorylation of AMPK substrates by 14%

• PGC-1α protein levels by 22%

• Mitochondrial protein synthesis rates by 55%

• Basal ATP synthase-dependent oxygen consumption by 13%

• Maximal uncoupled oxygen consumption by 15%

Using AMPD3 antibodies, researchers can:

• Monitor changes in AMPD3 expression during muscle atrophy conditions

• Perform co-immunoprecipitation to identify AMPD3 interaction partners

• Analyze subcellular localization of AMPD3 during different stages of atrophy

• Evaluate the efficacy of interventions designed to modulate AMPD3 expression or activity

What is known about AMPD3 deficiency in immune system development?

Mutations in AMPD3 strongly correlate with a reduction in naive CD4+ and CD8+ T-cell populations in peripheral blood, but notably not in secondary lymphoid organs. This relationship was discovered through N-ethyl-N-nitrosourea mutagenesis studies identifying five Ampd3 mutations (commanche, guangdong, carson, penasco, and taos) and confirmed through targeted ablation of Ampd3 .

AMPD3 antibodies can be valuable tools for:

• Phenotyping immune cell populations in AMPD3-deficient models

• Investigating cellular signaling pathways altered in AMPD3-deficient immune cells

• Monitoring AMPD3 expression in various immune cell lineages during development and activation

How does AMPD3 influence cellular metabolism beyond ATP regulation?

AMPD3 overexpression substantially alters cellular metabolism through multiple pathways:

• Purine metabolism: AMPD3 increases IMP production and its subsequent catabolites (inosine, hypoxanthine, xanthine, uric acid) while decreasing succinyl-AMP levels.

• Oxidative stress: Increased hypoxanthine and xanthine oxidation to uric acid by xanthine oxidoreductase (XOR) generates reactive oxygen species. Evidence includes elevated oxidized glutathione and methionine sulfoxide levels in AMPD3-expressing cells.

• Metabolomic impact: Out of 639 identified intracellular metabolites, 191 were significantly altered by AMPD3 overexpression, with the most affected pathways being:

  • Purine metabolism

  • Branched chain amino acid (leucine, isoleucine, valine) metabolism

  • Glycolysis

  • Ceramide metabolism

These changes occurred independently of gene expression changes, as RNA sequencing revealed only 30 out of 21,995 detected transcripts were significantly different between AMPD3-overexpressing and control cells .

What is the relationship between AMPD3 and AMPK/PGC-1α signaling pathways?

AMPD3 overexpression has time-dependent effects on AMPK/PGC-1α signaling:

• Short-term effects (24 hours): AMPD3 decreases ATP concentrations while maintaining ATP/ADP and ATP/AMP ratios, resulting in no immediate changes in AMPK phosphorylation (pAMPK/AMPK) or PGC-1α protein levels.

• Prolonged effects (48 hours): AMPD3 overexpression significantly reduces:

  • pAMPK/AMPK ratio by 24%

  • Phosphorylation of AMPK substrates by 14%

  • PGC-1α protein levels by 22%

  • Mitochondrial protein synthesis rates by 55%

  • Mitochondrial respiratory function

The data suggests AMPD3-induced metabolic changes precede reductions in AMPK signaling, gene expression, and mitochondrial protein synthesis, indicating that altered metabolism may be a driver rather than a consequence of reduced oxidative capacity .

How can multiple AMPD3 antibodies be used in conjunction to validate experimental findings?

Using multiple antibodies targeting different AMPD3 epitopes can strengthen research findings:

• Epitope verification: Compare results from monoclonal (e.g., AMPD3/901) and polyclonal (e.g., 23997-1-AP) antibodies to confirm specificity.

• Cross-species validation: Utilize antibodies with different species reactivity profiles to confirm findings across experimental models:

  • AMPD3/901 (human-specific)

  • 23997-1-AP (human, mouse, rat reactivity)

• Application-specific optimization: Different antibodies may perform optimally in different applications:

  • Western blot: Polyclonal antibodies may detect multiple isoforms (observed at both 70 kDa and 90 kDa)

  • IHC: Monoclonal antibodies may provide cleaner background and higher specificity

  • IP/Co-IP: Validate interactions using reciprocal pull-downs with different antibodies

• Knockout/knockdown controls: Validate antibody specificity using AMPD3-deficient models, which have been reported in literature .

How can researchers address variable molecular weight detection of AMPD3 in Western blotting?

AMPD3 protein can be detected at different molecular weights:

• Theoretical molecular weight: 90 kDa (based on amino acid sequence)

• Reported observed weights: 70 kDa and 90 kDa

This variability may be due to:

• Post-translational modifications: Phosphorylation, glycosylation, or proteolytic processing

• Isoform expression: Different splice variants across tissues

• Species differences: Human vs. mouse or rat AMPD3

• Sample preparation: Denaturing conditions affecting protein structure

To address this variability:

• Use positive controls such as RBC lysates, fetal liver, spleen, or placenta tissues

• Include loading controls and molecular weight markers

• Validate with multiple antibodies targeting different epitopes

• Perform antibody validation using siRNA knockdown or CRISPR knockout models

• Document specific sample preparation methods in publications

What are the most common false positive/negative scenarios when using AMPD3 antibodies?

Common issues with AMPD3 antibody specificity:

False Positives:

• Cross-reactivity with other AMPD family members (AMPD1, AMPD2) due to sequence homology

• Non-specific binding in tissues with high endogenous peroxidase activity

• Background staining in tissues with high erythrocyte content due to endogenous AMPD3

False Negatives:

• Inadequate antigen retrieval, especially in FFPE tissues

• Over-fixation leading to epitope masking

• Degradation of AMPD3 protein during sample preparation

• Use of incompatible detection systems

Mitigation strategies:

• Include both positive controls (RBCs, fetal liver, spleen, placenta) and negative controls (omitting primary antibody)

• Optimize antigen retrieval methods (comparing citrate buffer pH 6.0 vs. Tris-EDTA pH 9.0)

• Validate findings using alternative detection methods (e.g., qRT-PCR for mRNA expression)

• Use multiple antibodies targeting different epitopes

How should researchers interpret contradictory AMPD3 expression data across different detection methods?

When facing contradictory results between different detection methods:

• Method-specific limitations:

  • IHC provides spatial information but may lack quantitative precision

  • Western blotting is quantitative but loses spatial information

  • qRT-PCR measures mRNA levels that may not correlate with protein expression

  • Flow cytometry measures single-cell expression but requires cell dissociation

• Validation approaches:

  • Confirm antibody specificity using knockout/knockdown controls

  • Compare protein expression (Western blot/IHC) with mRNA expression (qRT-PCR)

  • Use multiple antibodies targeting different epitopes

  • Consider cell/tissue heterogeneity when interpreting whole-tissue lysate results

• Contextual factors:

  • AMPD3 expression can vary significantly between normal and pathological states

  • Down-regulation observed in HNSCC correlates with advanced tumor stages

  • Expression patterns differ between peripheral blood and secondary lymphoid organs

  • Different cell types within the same tissue may express AMPD3 at varying levels

Case example: In HNSCC research, AMPD3 down-regulation was validated by multiple methods (qRT-PCR and IHC), with protein expression patterns compatible with gene expression levels detected by qRT-PCR .

How can AMPD3 antibodies be utilized to study the relationship between metabolic dysfunction and immune cell development?

Given the dual involvement of AMPD3 in both metabolic regulation and immune cell development, several innovative research approaches emerge:

• Metabolic profiling of immune cells: Using AMPD3 antibodies for immunoprecipitation followed by metabolomic analysis to identify metabolites associated with AMPD3 activity in different immune cell subsets.

• Single-cell analysis: Combining AMPD3 antibodies with other immune markers in multiparameter flow cytometry or mass cytometry to correlate AMPD3 expression with metabolic states and functional phenotypes at the single-cell level.

• Tissue-specific regulation: Using tissue microarrays and AMPD3 immunostaining to compare expression patterns between peripheral blood and lymphoid organs, potentially revealing tissue-specific regulatory mechanisms explaining the observed differences in naive T-cell populations.

• Developmental timeline studies: Tracking AMPD3 expression during immune cell development to identify critical checkpoints where metabolic regulation influences cell fate decisions .

What is the potential for AMPD3 as a therapeutic target in cancer and muscle atrophy conditions?

Based on existing research findings, AMPD3 presents distinctive therapeutic opportunities:

• Cancer therapy approaches:

  • Since AMPD3 down-regulation correlates with worse prognosis in HNSCC, therapies that restore AMPD3 expression might improve patient outcomes

  • AMPD3 overexpression reduced cellular proliferation but increased migration/invasion, suggesting complex effects requiring targeted modulation rather than simple inhibition

  • Dual-targeting strategies addressing both AMPD3 and migration pathways might be necessary

• Muscle atrophy interventions:

  • AMPD3 inhibition might preserve adenine nucleotide pools and prevent mitochondrial dysfunction during atrophy

  • Targeting the downstream consequences of AMPD3 activity (e.g., XOR inhibition to prevent oxidative stress)

  • Timing considerations are crucial as metabolic alterations precede changes in AMPD/PGC-1α/mitochondrial protein synthesis

• Biomarker applications:

  • AMPD3 expression levels could serve as prognostic biomarkers in cancers

  • Monitoring AMPD3 activity might help identify early stages of muscle atrophy

  • AMPD3 antibodies could facilitate patient stratification for targeted therapies

This emerging field requires further validation through animal models and carefully designed clinical studies to determine the therapeutic potential of AMPD3 modulation.